WellCare, Centene reportedly interested in Aetna’s Medicare Advantage business

| | Health Exec | Economics

Aetna is looking to jettison its Medicare Advantage plans in order to placate antitrust concerns at the Department of Justice over its proposed merger with Humana, and Reuters is reporting at least two companies are competing for that portfolio.

Sources “familiar with the matter” say WellCare and Centene have submitted for bids for plans that cover around 350,000 patients, with a possible sale price of $1 billion.

To read more on the potential sale and how it may affect regulators’ final decision on the Aetna-Humana deal, click on the link below: 

Exclusive: WellCare, Centene make offers for Aetna assets - sources

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.